OBIO - Orchestra BioMed Holdings, Inc.
About Orchestra BioMed Holdings, Inc. (https://orchestrabiomed.com)
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| David Hochman | Founder, Chairman of the Board of Directors & Chief Executive Officer | 1975 | $1,179,259 USD |
| Darren R. Sherman | Founder, President, Chief Operating Officer & Director | 1971 | $1,041,640 USD |
| Andrew Lawrence Taylor | Chief Financial Officer | 1971 | $766,677 USD |
| Avraham Matityahu Fischer | Senior Vice President of Medical Affairs & Innovation | 1956 | – |
| Bob Laughner | Senior Vice President of Regulatory & Quality | – | – |
| Hans-Peter Stoll | Senior Vice President & Medical Director | – | – |
| Juan Lorenzo | Senior Vice President of Product Development | – | – |
| Lisa Daniels | Vice President of Human Resources | – | – |
| William Reed Little | Executive Vice President of Corporate Development & Strategy | 1971 | – |
| Yuval Hay Mika D.Sc | GM & Chief Technology Officer of Bioelectronic Therapies | 1959 | – |